Singular Health nets US$500,000 from US healthcare licence rollout

Singular Health Group has ticked off another key commercial milestone in the United States after receiving US$500,000 (A$698,500) from Provider Network Solutions Group (PNS) following the rollout of a further 500 licences for its 3DICOM MD platform.

The payment represents the balance of licence fees due under the binding enterprise agreement signed with PNS in June last year and brings total deployed licences across the network to 1000, fulfilling the contract’s initial rollout obligations.

PNS is a US-based healthcare services organisation managing care for more than 4 million lives across Florida, Texas and Puerto Rico. The group focuses on improving efficiencies across its provider network, particularly by reducing unnecessary duplication in medical imaging and improving access to patient data across multiple practitioners.

Singular Health’s 3DICOM MD platform has been specifically designed to address these inefficiencies by enabling clinicians to securely view, share and manage three‑dimensional medical imaging records across multiple and often disparate systems.

The company says enterprise use is progressing positively, with increasing adoption of its new platform embedded directly in everyday clinical workflows.

The receipt of this payment and the deployment of the next tranche of licences represent confirmation by PNS of the value of the 3DICOM MD® platform and are important milestones in scaling our commercial reach through PNS and its network and beyond.

Feedback from the latest rollout so far indicates the platform is delivering measurable cost savings, mainly by reducing duplicate imaging requests and improving interoperability between providers.

Provider Network Solutions chief executive officer Dr Jose Pelayo said his organisation views the potential savings of between three and five per cent of the US$35 per member per month in duplicated imaging costs as a material benefit.

The latest deployment further expands the reach and scale of Singular Health’s technology across the PNS ecosystem, where clinical adoption continues to gain momentum.

Notably, with the initial rollout now complete and payments up to date, discussions have begun between Singular Health and PNS regarding renewal and potential expansion of their mutual licensing arrangement.

Any extension of the arrangement would likely build on the existing footprint and could open the door to a wider deployment across PNS’s broader partner and joint venture network in the United States.

This milestone follows Singular Health’s June 2025 enterprise contract with PNS, valued at US$1.3 million, which combined the licence fees with development and integration work to embed the 3DICOM MD platform within the PNS network.

That agreement marked the company’s first successful, large-scale U.S. enterprise hurdle and has laid the groundwork for opportunities to expand nationally.

With clinical use on a strong growth path, timely payments landing and renewal talks underway, Singular Health appears to be steadily converting its US enterprise strategy into strong commercial traction.

If Singular’s momentum continues, its relationship with PNS could prove a pivotal reference point as the company pursues further large-scale healthcare networks across the United States.

Is your ASX-listed company doing something interesting? Contact:matt.birney@wanews.com.au